FRANKFURT (Reuters) – Novartis on Tuesday raised its full-year earnings outlook, citing a strong growth momentum.
The Swiss drugmaker said in a statement that when excluding Sandoz, the generic-drug division that will be spun off during the second half of the year, group core operating income would grow by a “high single digit to low double digit” percentage.
It had previously forecast a “mid-to-high single digit” increase.
(Reporting by Ludwig Burger, Editing by Rachel More)
